---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-24-000048"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:23:56.725000+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nurix Therapeutics Q1 FY2024 revenue $16.6M, net loss $41.5M; Gilead collaboration extended

## Summary
- Revenue $16.6M (up 31% YoY); net loss $41.5M ($0.76/sh) vs $40.7M ($0.75/sh) prior year.
- Cash $254.3M vs $295.3M at Nov 30, 2023; R&D spend $50.0M (up 9% YoY).
- Gilead extended collaboration by 2 years, paying $15M extension fee; total potential milestones up to $1.7B.
- Sanofi extended STAT6 program; Nurix expects to nominate clinical candidate in 12 months.
- FDA lifted partial clinical hold on NX-2127 (BTK degrader) in March 2024; enrollment to reinitiate.

## SEC filing metadata
- accession: 0001549595-24-000048
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000048/0001549595-24-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000048/nrix-20240410.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-24-000048
- JSON: https://secwatch.observer/filing/0001549595-24-000048.json
- Plain text: https://secwatch.observer/filing/0001549595-24-000048.txt

## Key facts
- Earnings Releases
  Nurix Therapeutics, Inc. reported financial results for first quarter ended February 29, 2024.
  - Period: first quarter ended February 29, 2024
  - Result: reported results
  source text: Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000048/0001549595-24-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.